Sign in

CIK 0001287098

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

MAXCYTE, INC.

Sign in to watch
Ticker
MXCT
Exchange
Nasdaq
Industry
Services-Commercial Physical & Biological Research
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
522210438
Phone
+1 301-517-5556
Business address
9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, MD, 20850
Former names
MAXCYTE INC
  1. 4 Grant or award Director acquired 21,367 shares (grant or award)
  2. 4 Open-market buy President and CEO bought 100,000 shares at an average $4.89 ($489,066)
  3. 4 Planned sale Director sold 5,000 shares at $4.41 ($22,025)
  4. 4 Grant or award EVP, GLOBAL SALES & MARKETING acquired 25,000 shares (grant or award)
  5. 4 Grant or award GENERAL COUNSEL acquired 3,913 shares (grant or award)
  6. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 81,250 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Planned sale Director sold 5,000 shares at $4.60 ($23,005)
  9. 4 Planned sale Director sold 5,000 shares at $5.12 ($25,585)
  10. 4 Derivatives Options or other derivatives
  11. 4 Planned sale Director sold 5,000 shares at $4.53 ($22,650)
  12. 4 Open-market sale President and CEO sold 124,450 shares at an average $5.14 ($639,405)
  13. 4 Open-market sale President and CEO sold 25,550 shares at $5.00 ($127,750)
  14. 4 Planned sale Director sold 5,000 shares at $4.59 ($22,950)
  15. 4 Planned sale Director sold 10,000 shares at $3.71 ($37,100)
  16. 4 Planned sale Director sold 5,000 shares at $3.70 ($18,500)
  17. 4 Planned sale Director sold 5,000 shares at $4.75 ($23,750)
  18. 4 Planned sale President and CEO sold 30,000 shares at an average $5.03 ($150,852)
  19. 4 Planned sale Director sold 15,000 shares at an average $4.44 ($66,603)
  20. 4 Derivatives Options or other derivatives

Page 4 of 9 · 163 filings